Last reviewed · How we verify

NCT04503421

Use of Blood Flow Restriction (BFR) Therapy in Post-operative Rehabilitation Following Distal Biceps Tendon Repair

Completed NA Last updated 8 December 2023
What this trial tests

NA trial testing Blood Flow Restriction Therapy in Bicep Tendon Rupture in 64 participants. Completed in 15 September 2021.

Timeline
15 August 2020
Primary endpoint
15 August 2021
15 September 2021

Quick facts

Lead sponsorHenry Ford Health System
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment64
Start date15 August 2020
Primary completion15 August 2021
Estimated completion15 September 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Henry Ford Health System — full company profile →

Who can join

Adults 18 to 80, any sex, with Bicep Tendon Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this investigation is to determine if using BFR during postoperative therapy would lead to increased and expedited strength gains. Additionally, the investigators would like to determine if BFR is beneficial in preventing muscle atrophy and fatty infiltration in the setting of bicep tendon tears, due to the altered tension-length relationship following surgery. The study will also look at patient reported outcomes metrics and pain scores to determine if BFR has a significant impact on the patient experience surrounding distal biceps tear and surgical repair

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood Flow Restriction Therapy

Trials testing the same drug.

Other Henry Ford Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04503421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing